---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: VX22-147-010"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: VX22-147-010. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 2 further headings. 12 evidence topics quoted from 1 source."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence/vx22-147-010"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: VX22-147-010

<a id="heading-3.1.8"></a>

## 3.1.8 VX22-147-010

<a id="heading-3.1.8.1"></a>

### 3.1.8.1 Objective

<a id="topic-3.1.8.1-1"></a>

#### Purpose stated in the registry record

> “The purpose of the study is to evaluate the relative bioavailability (BA) and the effect of food on the pharmacokinetics (PK), and the safety and tolerability of VX-147 test tablet formulation.”

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

<a id="heading-3.1.8.2"></a>

### 3.1.8.2 Location and Study Date

<a id="topic-3.1.8.2-1"></a>

#### Study dates and status in the registry record

| Field | Registry entry |
| --- | --- |
| Recruitment status | “Completed” |
| Study start (actual) | “2023-07-19” |
| Primary completion (actual) | “2023-09-02” |
| Study completion (actual) | “2023-09-02” |
| First posted | “2023-07-21” |
| Last update posted | “2023-09-13” |
| Other study ID numbers | “VX22-147-010” |

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

<a id="topic-3.1.8.2-2"></a>

#### Study location in the registry record

> “This study has 1 location”
> “Salt Lake City, Utah, United States, 84124”

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

<a id="heading-3.1.8.3"></a>

### 3.1.8.3 Study Design

<a id="topic-3.1.8.3-1"></a>

#### Phase 1, open-label, randomized crossover design

> “A Phase 1, Open Label, Randomized, Crossover Study Evaluating the Relative Bioavailability and Food Effect of a VX-147 Test Tablet Formulation Compared to a Reference Tablet Formulation in Healthy Adult Subjects”

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

<a id="topic-3.1.8.3-2"></a>

#### Design details in the registry record

| Field | Registry entry |
| --- | --- |
| Study type | “Interventional” |
| Phase | “Phase 1” |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

<a id="heading-3.1.8.4"></a>

### 3.1.8.4 Eligibility Criteria

<a id="topic-3.1.8.4-1"></a>

#### Key criteria in the registry record

> “Body mass index (BMI) of 18.0 to 32.0 kilogram per square meter (kg/m^2), inclusive”
> “A total body weight greater than 50 kg”
> “History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug”
> “Any condition possibly affecting drug absorption”

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

<a id="topic-3.1.8.4-2"></a>

#### Age range and healthy volunteers

| Field | Registry entry |
| --- | --- |
| Ages eligible | “18 Years to 55 Years” |
| Sexes eligible | “All” |
| Accepts healthy volunteers | “Yes” |

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

<a id="heading-3.1.8.5"></a>

### 3.1.8.5 Treatment

<a id="topic-3.1.8.5-1"></a>

#### Three treatment sequences of test and reference tablets, fed and fasted

> “Participants will receive VX-147 reference tablet under fasted condition in Treatment Period 1, then VX-147 test tablet under fed condition in Treatment Period 2, and VX-147 test tablet under fasted condition in Treatment Period 3. A washout period of 5 days will be maintained between 3 treatment periods.”
> “Participants will receive VX-147 test tablet under fed condition in Treatment Period 1, then VX-147 test tablet under fasted condition in Treatment Period 2, and VX-147 reference tablet under fasted condition in Treatment Period 3. A washout period of 5 days will be maintained between 3 treatment periods.”
> “Participants will receive VX-147 test tablet under fasted condition in Treatment Period 1, then VX-147 reference tablet under fasted condition in Treatment Period 2, and VX-147 test tablet under fed condition in Treatment Period 3. A washout period of 5 days will be maintained between 3 treatment periods.”
> “Tablets for oral administration.”

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

<a id="heading-3.1.8.6"></a>

### 3.1.8.6 Study Outcomes

<a id="heading-3.1.8.6.1"></a>

#### 3.1.8.6.1 Rationale for Using Relative Bioavailability and Food Effect on Cmax and AUC0-inf as the Primary Endpoints

<a id="topic-3.1.8.6.1-1"></a>

##### Registered primary and secondary outcomes

| Outcome | Measure | Time frame |
| --- | --- | --- |
| Primary | “Maximum Observed Plasma Concentration (Cmax) of VX-147 Test Compared to VX-147 Reference” | “From Day 1 up to Day 16” |
| Primary | “Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-147 Test Compared to VX-147 Reference” | “From Day 1 up to Day 16” |
| Primary | “Cmax of VX-147 Test Compared Under Fed Versus Fasted State” | “From Day 1 up to Day 16” |
| Primary | “AUC(0-inf) of VX-147 Test Compared Under Fed Versus Fasted State” | “From Day 1 up to Day 16” |
| Secondary | “Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious AEs” | “From Day -1 up to Day 27” |

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

<a id="heading-3.1.8.7"></a>

### 3.1.8.7 Statistical Analysis Description

<a id="heading-3.1.8.7.1"></a>

#### 3.1.8.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.8.7.1-1"></a>

##### Enrollment in the registry record

| Field | Registry entry |
| --- | --- |
| Enrollment (actual) | “21” |

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

<a id="heading-3.1.8.7.2"></a>

#### 3.1.8.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.8.8"></a>

### 3.1.8.8 Results

<a id="heading-3.1.8.8.1"></a>

#### 3.1.8.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.8.8.2"></a>

#### 3.1.8.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.8.8.3"></a>

#### 3.1.8.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.8.8.4"></a>

#### 3.1.8.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.8.8.5"></a>

#### 3.1.8.8.5 Safety Results

No evidence found.

<a id="heading-3.1.8.9"></a>

### 3.1.8.9 Study Limitations

<a id="topic-3.1.8.9-1"></a>

#### Summary: study limitations

VX22-147-010 enrolled 21 healthy adults aged 18 to 55 years at one United States site and compared a test tablet with a reference tablet, and the test tablet fed with fasted, in a three-period crossover with 5-day washouts. The study was completed on 2023-09-02, but the ClinicalTrials.gov record lists no posted results, and no publication or congress abstract reporting its results was identified. The registry record does not state the dose or the composition of the test meal.

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

<a id="topic-3.1.8.9-2"></a>

#### No results posted in the registry record

> “No Results Posted”

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
